View Older Stories View More Recent Stories

Jun 20, 2023 07:30AM Precigen Receives Breakthrough Therapy Designation for PRGN-2012 AdenoVerse™ Immunotherapy for the Treatment of Recurrent Respiratory Papillomatosis
Jun 5, 2023 04:06PM Precigen Inc. (PGEN) Reports Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T Cells
Jun 5, 2023 04:05PM Precigen Announces Positive Phase 1 Data for PRGN-3005 Autologous UltraCAR-T® Cells Manufactured Overnight for Infusion Next Day to Advanced Stage Platinum Resistant Ovarian Cancer Patients
Jun 5, 2023 05:55AM Precigen Inc. (PGEN) Presents Positive Phase 1 Data for Off-the-Shelf PRGN-2009
Jun 3, 2023 12:00PM Precigen Announces Positive Phase 1 Data for Off-the-Shelf PRGN-2009 AdenoVerse™ Immunotherapy Alone and in Combination with an Investigational Checkpoint Inhibitor in Patients with Recurrent/Metast
May 31, 2023 08:05AM Precigen Receives FDA Clearance of IND to Initiate Phase 2 Study of PRGN-2009 Off-the-Shelf AdenoVerse Immunotherapy in Combination with Pembrolizumab to Treat Patients with Recurrent or Metastatic Ce
May 10, 2023 08:00AM Precigen Reports First Quarter 2023 Financial Results and Business Updates
Apr 26, 2023 04:05PM Precigen to Present Latest Clinical Advancements for PRGN-3005 UltraCAR-T® and PRGN-2009 Off-the-Shelf AdenoVerse™ Immunotherapy at the 2023 ASCO Annual Meeting
Apr 17, 2023 09:02AM Precigen Inc. (PGEN) Presents Preclinical Data
Apr 17, 2023 09:01AM Precigen Presents Preclinical Data for the Next Generation Mesothelin UltraCAR-T® with Intrinsic PD-1 Blockade at the AACR Annual Meeting 2023
Apr 3, 2023 04:31PM Precigen Inc. (PGEN) Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T
Apr 3, 2023 04:30PM Precigen Regains Exclusive Rights to Proven CAR-T Targets, CD19 and BCMA, to Enable Unencumbered Development and Commercialization of UltraCAR-T®
Mar 29, 2023 08:06AM Precigen (PGEN) Reports First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007
Mar 29, 2023 08:05AM Precigen Announces Further Advancement of UltraCAR-T® Platform with First Patient Dosed in Phase 1/1b Dose Escalation/Dose Expansion Study of PRGN-3007 in Advanced ROR1+ Hematological and Solid Tumor
Mar 28, 2023 08:05AM Precigen to Participate in a Virtual Fireside Chat at Cantor's "The Future of Oncology" Virtual Symposium
Mar 6, 2023 04:05PM Precigen Reports Fourth Quarter and Full Year 2022 Financial Results and Business Updates
Jan 12, 2023 04:58AM Precigen (PGEN) Provides Pipeline and Corporate Updates
Jan 11, 2023 06:45PM Precigen Provides Pipeline and Corporate Updates at the 41st Annual J.P. Morgan Healthcare Conference
Dec 19, 2022 04:05PM Precigen to Present at the 41st Annual J.P. Morgan Healthcare Conference
Dec 12, 2022 07:01PM Precigen Announces Positive Phase 1 Dose Escalation Data for Autologous PRGN-3006 UltraCAR-T® Manufactured Overnight for Next Day Infusion in Relapsed or Refractory Acute Myeloid Leukemia Patients
Nov 9, 2022 04:05PM Precigen Reports Third Quarter 2022 Financial Results and Progress of Clinical Programs
Nov 2, 2022 04:30PM Precigen to Announce Third Quarter 2022 Financial Results on November 9th
Sep 21, 2022 04:31PM Precigen (PGEN) Appoints Rutul R. Shah as COO
Sep 21, 2022 04:31PM Precigen (PGEN) Appoints Rutul R. Shah as COO
Sep 21, 2022 04:30PM Precigen Names Rutul R. Shah Chief Operating Officer
Sep 1, 2022 08:05AM Precigen to Participate in the 2022 Wells Fargo Healthcare Conference
Aug 22, 2022 08:05AM Precigen Completes Sale of Non-Healthcare Subsidiary Trans Ova Genetics
Aug 8, 2022 04:05PM Precigen Reports Second Quarter and First Half 2022 Financial Results
Aug 1, 2022 04:05PM Precigen to Announce Second Quarter and First Half 2022 Financial Results on August 8th
Jul 5, 2022 08:05AM Precigen Inc. (PGEN) to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Jul 5, 2022 08:05AM Precigen Enters into Agreement to Divest Non-Healthcare Subsidiary Trans Ova Genetics
Jun 27, 2022 04:05PM Precigen to Participate in the Stifel 2022 Virtual Cell Therapy Summit
May 17, 2022 04:05PM Precigen to Participate in the 2022 H.C. Wainwright Global Investment Conference
May 9, 2022 04:05PM Precigen Reports First Quarter 2022 Financial Results and Business Updates
Apr 4, 2022 08:05AM Precigen Inc. (PGEN) Granted Fast Track Designation for PRGN-3006 UltraCAR-T
Apr 4, 2022 08:05AM Precigen Receives Fast Track Designation for PRGN-3006 UltraCAR-T® in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Mar 1, 2022 08:00AM Precigen Reports Fourth Quarter and Full Year 2021 Financial Results
Jan 12, 2022 04:32PM Precigen Inc. (PGEN) Announces Corporate and Pipeline Update
Jan 12, 2022 04:30PM Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare Conference
Jan 5, 2022 04:05PM Precigen to Present at the 40th Annual J.P. Morgan Healthcare Conference
Dec 13, 2021 05:06PM Precigen Inc. (PGEN) Reports Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T in Relapsed or Refractory Acute Myeloid Leukemia
Dec 13, 2021 05:05PM Precigen Announces Positive Interim Phase 1 Data for PRGN-3006 UltraCAR-T® in Relapsed or Refractory Acute Myeloid Leukemia
Nov 10, 2021 04:05PM Precigen to Present at the Stifel 2021 Virtual Healthcare Conference
Nov 4, 2021 09:15AM Precigen Inc. (PGEN) Reports Significant Clinical Progress for UltraCAR-T and AdenoVerse Therapies
Nov 4, 2021 09:15AM Precigen Achieves Significant Clinical Progress for UltraCAR-T® and AdenoVerse™ Therapies
Oct 27, 2021 04:38PM Precigen to Host R&D Update Virtual Event on November 4th to Share Clinical Developments
Oct 26, 2021 08:05AM Precigen Inc. (PGEN) Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
Oct 26, 2021 08:05AM Precigen Announces Clearance of IND to Initiate Phase 1/1b Study for PRGN-3007 UltraCAR-T® in Advanced ROR1+ Hematological and Solid Tumors
Oct 12, 2021 08:06AM Precigen Inc. (PGEN) Appoints Harry Thomasian Jr as CFO
Oct 12, 2021 08:05AM Precigen Appoints Harry Thomasian Jr. as Chief Financial Officer
View More Recent Stories View Older Stories